Prostatectomy News and Research

RSS

New findings could change treatment practice and lengthen survival for men with pN1 prostate cancer

Men with microscopic evidence of prostate cancer spreading to their pelvic lymph nodes (LNs) following the surgical resection of the prostate and pelvic lymph nodes (LN) are at a very high risk of dying from prostate cancer. Pelvic LN radiation therapy (RT) is a potentially curative treatment.

15 Mar 2022

Henry Ford surgeons use unique approach to perform first precision prostatectomy

Surgeons at Henry Ford Health System's Vattikuti Urology Institute performed what is believed to be the first precision prostatectomy through the bladder using a single port robotic surgical system.

13 Dec 2021

Fewer, higher doses of post-prostatectomy radiation therapy does not increase long-term side effects

Using fewer-;but higher-;doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.

25 Oct 2021

Genetic biomarker test predicts how men with high-risk prostate cancer will respond to treatment

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.

25 Oct 2021

Researchers identify genes associated with biochemical recurrence in prostate adenocarcinoma

Aging-US published "Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma" which reported that the authors aimed to identify the potential prognostic genes in the prostate adenocarcinoma microenvironment and to estimate the causal effects simultaneously.

20 Aug 2021

Prostate cancer survivors have persistent fear of cancer recurrence, study reveals

A recent study reveals that some prostate cancer survivors have a persistent fear of cancer recurrence even many years after diagnosis and treatment.

19 Aug 2021

Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis

Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

7 Jul 2021

Multimodality therapy critical for treating more aggressive prostate cancers

Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center.

1 Jul 2021

New device can increase penile length and preserve erectile function in men after prostatectomy

A new type of penile traction therapy (PTT) device can increase penile length and preserve erectile function in men who have undergone prostate cancer surgery (prostatectomy), reports a clinical trial in The Journal of Urology®, Official Journal of the American Urological Association (AUA).

1 Jun 2021

Topical drug regenerates, restores function of erectile nerves damaged by radical prostatectomy

Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer.

19 Apr 2021

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

The National Comprehensive Cancer Network and the NCCN Foundation today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program.

15 Apr 2021

Genomic and immune indicators can help identify prostate cancer patients at high risk of lethal outcomes

Prostate cancer is one of the most common cancers among men in the United States. One in nine men will be diagnosed during his lifetime.

15 Dec 2020

UCLA, UCSF obtain FDA approval for PSMA PET imaging in men with prostate cancer

The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated.

2 Dec 2020

Cost of prostate cancer treatment can be a major source of stress for men, their families

For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

1 Dec 2020

Medical mistrust can make African Americans to regret their choice of treatment for prostate cancer

Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer.

25 Nov 2020

Metastasis-free survival is strongly linked to overall survival of men treated for prostate cancer

An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage radiotherapy (SRT) following prostatectomy for recurrent prostate cancer indicated that, while biochemical failure (BF) was not a strong surrogate endpoint to determine overall survival (OS), metastasis-free survival (MFS) was in this patient population.

27 Oct 2020

Cerenkov luminescence imaging can accurately assess surgical margins during radical prostatectomy

A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of the Journal of Nuclear Medicine.

7 Oct 2020

High-intensity focused ultrasound technology shows promising outcomes for prostate cancer

High-intensity focused ultrasound (HIFU) - a technology used to treat localized prostate cancer - has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology®, Official Journal of the American Urological Association (AUA).

9 Sep 2020

Focal high-intensity focused ultrasound ablation is an effective treatment for prostate cancer

For some prostate cancer patients, radical treatment (surgery or radiation) are treatment standards. However, these procedures may cause side effects including urinary incontinence or impotency.

8 Sep 2020

Dartmouth receives $2.5 million to develop device for detecting tumor left behind during surgery

Dartmouth engineers have been awarded a $2.5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop and test a device--a microendoscopic electrical impedance sensing probe-- that could be used by surgeons to detect prostate cancer still left in the body during surgery.

25 Aug 2020